{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:18:05Z","timestamp":1793395085027,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.canlet.2024.216807","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T09:19:42Z","timestamp":1709889582000},"page":"216807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["LRP1 induces anti-PD-1 resistance by modulating the DLL4-NOTCH2-CCL2 axis and redirecting M2-like macrophage polarisation in bladder cancer"],"prefix":"10.1016","volume":"593","author":[{"given":"Hansen","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangmin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anze","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuyuan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guannan","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3801-8682","authenticated-orcid":false,"given":"Qiong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhuan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazheng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengju","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.canlet.2024.216807_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"Ca - Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.canlet.2024.216807_bib2","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3322\/caac.21631","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"Ca - Cancer J. Clin."},{"issue":"11","key":"10.1016\/j.canlet.2024.216807_bib3","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41573-022-00538-9","article-title":"The expanding role for small molecules in immuno-oncology","volume":"21","author":"Offringa","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"19","key":"10.1016\/j.canlet.2024.216807_bib4","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"issue":"10122","key":"10.1016\/j.canlet.2024.216807_bib5","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"11","key":"10.1016\/j.canlet.2024.216807_bib6","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.canlet.2024.216807_bib7","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jamaoncol.2019.2311","article-title":"Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1","volume":"5","author":"Lee","year":"2019","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2024.216807_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13024-022-00560-w","article-title":"LRP1 is a neuronal receptor for \u03b1-synuclein uptake and spread","volume":"17","author":"Chen","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.canlet.2024.216807_bib9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev.biochem.71.110601.135342","article-title":"Lipoprotein receptors in the nervous system","volume":"71","author":"Herz","year":"2002","journal-title":"Annu. Rev. Biochem."},{"issue":"6","key":"10.1016\/j.canlet.2024.216807_bib10","first-page":"1432","article-title":"Decreased expression of both the low-density lipoprotein receptor-related protein\/alpha(2)-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression","volume":"56","author":"de Vries","year":"1996","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.canlet.2024.216807_bib11","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.cell.2012.10.028","article-title":"Convergent multi-miRNA targeting of ApoE drives LRP1\/LRP8-dependent melanoma metastasis and angiogenesis","volume":"151","author":"Pencheva","year":"2012","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.canlet.2024.216807_bib12","first-page":"2799","article-title":"Increased expression of low density lipoprotein receptor-related protein\/alpha2-macroglobulin receptor in human malignant astrocytomas","volume":"57","author":"Yamamoto","year":"1997","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.canlet.2024.216807_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186649","article-title":"Expression of LDL receptor-related proteins (LRPs) in common solid malignancies correlates with patient survival","volume":"12","author":"Gonias","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2024.216807_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1113756","article-title":"LDL receptor related protein 1 is an adverse prognostic biomarker that correlates with stromal remodeling and macrophages infiltration in bladder cancer","volume":"14","author":"Du","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2024.216807_bib15","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1186\/s12885-021-09006-w","article-title":"Identification of a novel metabolism-related gene signature associated with the survival of bladder cancer","volume":"21","author":"Li","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2024.216807_bib16","article-title":"Identification of an immune-related risk signature correlates with immunophenotype and predicts anti-PD-L1 efficacy of urothelial cancer","volume":"9","author":"Li","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"6","key":"10.1016\/j.canlet.2024.216807_bib17","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"7693","key":"10.1016\/j.canlet.2024.216807_bib18","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.canlet.2024.216807_bib19","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1200\/JCO.2012.44.3762","article-title":"Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy","volume":"31","author":"Ulloa-Montoya","year":"2013","journal-title":"J. Clin. Oncol. : Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2024.216807_bib20","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/s41467-017-01460-0","article-title":"Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma","volume":"8","author":"Lauss","year":"2017","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.canlet.2024.216807_bib21","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1038\/s41591-018-0247-8","article-title":"Publisher Correction: robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma","volume":"24","author":"Auslander","year":"2018","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.canlet.2024.216807_bib22","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s12276-020-00493-8","article-title":"Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer","volume":"52","author":"Cho","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"10.1016\/j.canlet.2024.216807_bib23","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1038\/s41467-019-12159-9","article-title":"DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load","volume":"10","author":"Jung","year":"2019","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.canlet.2024.216807_bib24","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.canlet.2024.216807_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"244","key":"10.1016\/j.canlet.2024.216807_bib26","doi-asserted-by":"crossref","first-page":"244ra91","DOI":"10.1126\/scitranslmed.3008970","article-title":"EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype","volume":"6","author":"Rebouissou","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.canlet.2024.216807_bib27","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sj\u00f6dahl","year":"2012","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"issue":"2","key":"10.1016\/j.canlet.2024.216807_bib28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216807_bib29","first-page":"3110","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"vol. 111","author":"Damrauer","year":"2014"},{"issue":"5","key":"10.1016\/j.canlet.2024.216807_bib30","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/jnci\/djx243","article-title":"Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinomas","volume":"110","author":"Mo","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.canlet.2024.216807_bib31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"issue":"9","key":"10.1016\/j.canlet.2024.216807_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107468","article-title":"pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels","volume":"9","author":"Geeleher","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.canlet.2024.216807_bib33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s12967-023-04161-z","article-title":"Fatty acids metabolism affects the therapeutic effect of anti-PD-1\/PD-L1 in tumor immune microenvironment in clear cell renal cell carcinoma","volume":"21","author":"Lin","year":"2023","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.canlet.2024.216807_bib34","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1038\/s41598-018-22126-x","article-title":"A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort","volume":"8","author":"Marzouka","year":"2018","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.canlet.2024.216807_bib35","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1053\/j.gastro.2023.02.005","article-title":"Disruption of SLFN11 deficiency-induced CCL2 signaling and macrophage M2 polarization potentiates anti-PD-1 therapy efficacy in hepatocellular carcinoma","volume":"164","author":"Zhou","year":"2023","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.canlet.2024.216807_bib36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-020-01165-x","article-title":"CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis","volume":"19","author":"Yang","year":"2020","journal-title":"Mol. Cancer"},{"issue":"20","key":"10.1016\/j.canlet.2024.216807_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.devcel.2021.09.015","article-title":"Low-density-lipoprotein-receptor-related protein 1 mediates Notch pathway activation","volume":"56","author":"Bian","year":"2021","journal-title":"Dev. Cell"},{"issue":"6","key":"10.1016\/j.canlet.2024.216807_bib38","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1534-5807(01)00091-0","article-title":"Xenopus neuralized is a ubiquitin ligase that interacts with XDelta1 and regulates Notch signaling","volume":"1","author":"Deblandre","year":"2001","journal-title":"Dev. Cell"},{"issue":"1","key":"10.1016\/j.canlet.2024.216807_bib39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1534-5807(02)00409-4","article-title":"Mind bomb is a ubiquitin ligase that is essential for efficient activation of Notch signaling by Delta","volume":"4","author":"Itoh","year":"2003","journal-title":"Dev. Cell"},{"issue":"5","key":"10.1016\/j.canlet.2024.216807_bib40","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.molcel.2015.01.019","article-title":"A tail of two sites: a bipartite mechanism for recognition of notch ligands by mind bomb E3 ligases","volume":"57","author":"McMillan","year":"2015","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.canlet.2024.216807_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2022.05.004","article-title":"Spatiotemporal co-dependency between macrophages and exhausted CD8(+) T cells in cancer","volume":"40","author":"Kersten","year":"2022","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.canlet.2024.216807_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2021.02.013","article-title":"Progressive immune dysfunction with advancing disease stage in renal cell carcinoma","volume":"39","author":"Braun","year":"2021","journal-title":"Cancer Cell"},{"issue":"20","key":"10.1016\/j.canlet.2024.216807_bib43","doi-asserted-by":"crossref","first-page":"9332","DOI":"10.7150\/thno.47137","article-title":"USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer","volume":"10","author":"Dai","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.canlet.2024.216807_bib44","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13046-020-01786-6","article-title":"Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8(+) T cell exclusion","volume":"40","author":"Fang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res. : CR"},{"issue":"1","key":"10.1016\/j.canlet.2024.216807_bib45","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/jcmm.14767","article-title":"An EMT-related gene signature for the prognosis of human bladder cancer","volume":"24","author":"Cao","year":"2020","journal-title":"J. Cell Mol. Med."},{"issue":"1","key":"10.1016\/j.canlet.2024.216807_bib46","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13046-022-02377-3","article-title":"TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K\/AKT pathway in bladder cancer","volume":"41","author":"Chi","year":"2022","journal-title":"J. Exp. Clin. Cancer Res. : CR"},{"issue":"7579","key":"10.1016\/j.canlet.2024.216807_bib47","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature16064","article-title":"Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer","volume":"527","author":"Zheng","year":"2015","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.canlet.2024.216807_bib48","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ccr.2009.01.023","article-title":"Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells","volume":"15","author":"Kudo-Saito","year":"2009","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.canlet.2024.216807_bib49","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-2463","article-title":"Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs)","volume":"22","author":"Alfaro","year":"2016","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res."},{"issue":"6","key":"10.1016\/j.canlet.2024.216807_bib50","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.ymthe.2021.02.006","article-title":"Tumor-derived exosomal microRNA-106b-5p activates EMT-cancer cell and M2-subtype TAM interaction to facilitate CRC metastasis","volume":"29","author":"Yang","year":"2021","journal-title":"Mol. Ther. : J. Am. Soc. Gene Therapy"},{"key":"10.1016\/j.canlet.2024.216807_bib51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13045-014-0087-z","article-title":"Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application","volume":"7","author":"Yuan","year":"2014","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2024.216807_bib52","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1172\/JCI78185","article-title":"NOTCH pathway inactivation promotes bladder cancer progression","volume":"125","author":"Maraver","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.canlet.2024.216807_bib53","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/nm.3678","article-title":"A new tumor suppressor role for the Notch pathway in bladder cancer","volume":"20","author":"Rampias","year":"2014","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.canlet.2024.216807_bib54","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41585-018-0005-1","article-title":"Unravelling disparate roles of NOTCH in bladder cancer","volume":"15","author":"Goriki","year":"2018","journal-title":"Nat. Rev. Urol."},{"issue":"12","key":"10.1016\/j.canlet.2024.216807_bib55","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1158\/1078-0432.CCR-15-2360","article-title":"Not all NOTCH is created equal: the oncogenic role of NOTCH2 in bladder cancer and its implications for targeted therapy","volume":"22","author":"Hayashi","year":"2016","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. for Cancer Res."},{"issue":"3","key":"10.1016\/j.canlet.2024.216807_bib56","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrurol.2016.22","article-title":"Bladder cancer: to be or NOTCH2 be?","volume":"13","author":"Fenner","year":"2016","journal-title":"Nat. Rev. Urol."},{"issue":"6","key":"10.1016\/j.canlet.2024.216807_bib57","doi-asserted-by":"crossref","first-page":"7970","DOI":"10.1096\/fj.201902659R","article-title":"CAFs-derived MFAP5 promotes bladder cancer malignant behavior through NOTCH2\/HEY1 signaling","volume":"34","author":"Zhou","year":"2020","journal-title":"Faseb. J. : OffO Publication Federation Am Soc. Exp. Bio."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524002003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524002003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T18:51:03Z","timestamp":1720291863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524002003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":57,"alternative-id":["S0304383524002003"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216807","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LRP1 induces anti-PD-1 resistance by modulating the DLL4-NOTCH2-CCL2 axis and redirecting M2-like macrophage polarisation in bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216807","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"216807"}}